EP4637929A1 — Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers
Assigned to Duke University · Expires 2025-10-29 · 1y expired
What this patent protects
Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one brain-excluded estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one brain-penetrating ER…
USPTO Abstract
Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one brain-excluded estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one brain-penetrating ER agonist or at least one brain-penetrating androgen receptor (AR) modulator. The brain-excluded ER modulating drug may be administered to a subject at a dose that results in from zero to minimal brain exposure.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.